What does STOP-IgAN tell us about how to treat IgA nephropathy?

Barratt J , Feehally J . IgA nephropathy. J Am Soc Nephrol 2005; 16;2088–97.

D'Amico G . Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24: 179–96.

Bartosik LP , Lajoie G , Sugar L . Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728–35.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Inter 2012; 2012; 2(suppl):139–274.

Kim J-K , Kim JH , Lee SC . Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol 2012; 7: 427–36. https://dx-doi-org.web.bisu.edu.cn/10.2215/CJN.04820511

Vecchio M , Bonerba B , Palmer SC . Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2015; 8:CD003965. https://dx-doi-org.web.bisu.edu.cn/10.1002/14651858.CD003965.pub2

Rauen T , Eitner F , Fitzner C . Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373: 2225–36. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1415463

Pozzi C , Andrulli S , Del Vecchio L . Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15: 157–63.

Pozzi C , Bolasco PG , Fogazzi GB . Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883–7.

Praga M , Gutiérrez E , González E . Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578–83.

Coppo R , Peruzzi L , Amore A . IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880–8.

Manno C , Torres DD , Rossini M . Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694–701. https://dx-doi-org.web.bisu.edu.cn/10.1093/ndt/gfp356

Geddes CC , Rauta V , Gronhagen-Riska C . A tricontinental view of IgA nephropathy. Nephrol Dial Transplant 2003; 18: 1541–8.

Yusuf S , Teo KK , Pogue J . Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.

Fried LF , Emanuele N , Zhang JH . Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892–903. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1303154

Parving H-H , Brenner BM , McMurray JJ . Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–13. https://dx-doi-org.web.bisu.edu.cn/10.1056/NEJMoa1208799

MHRA. Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings. Drug Safety Update 19 June 2014. https://www.gov.uk/drug-safety-update/combination-use-of-medicines-from-different-classes-of-renin-angiotensin-system-blocking-agents-risk-of-hyperkalaemia-hypotension-and-impaired-renal-function-new-warnings (accessed 11/2/16).